FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty												1				
1. Name and Address of Reporting Person *- WEISS MICHAEL S				2. Issuer Name and Ticker or Trading Symbol Checkpoint Therapeutics, Inc. [CKPT]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) 2 GANSEVOORT STREET, 9TH FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 06/10/2021						Officer (give title below) Other (specify below)							
(Street) NEW YORK, NY 10014			4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Form fi	6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqui						uired, Disp	ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)			(Instr. 8)		(A) or Disposed of (D)		D) Beneficia Reported	Beneficially Owned Following Reported Transaction(s)		Ownership Form:	Beneficial		
				(Month/Day	y/Year)		Code	V	Amou	nt (A) or (D)	Pric	(Instr. 3 a	nd 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
COMMO	N STOCE	ζ	06/10/2021				A		16,50 (1))2 A	\$ 0	78,782	<u>(2)</u>		I	See Note 3
				Derivative So			quired	onta he fo	ined in orm dis	n this fo splays a of, or Bei	rm a curr nefici	re not requently valides ally Owned	ction of inf uired to res I OMB con	spond unle	ess	1474 (9-02)
1 77:1 6		0 T .:	(6	e.g., puts, ca	lls, wa	ırranı	ts, opti	ions,	conver	tible secu	ırities	s)		0.31 1	6 10	la v
Security	Conversion or Exercise Price of Derivative Security		Execution Date any	te, if Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		and Expiration Date (Month/Day/Year)			Ar Ur Se			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivat Securit Direct or India	Beneficia Ownershi (Instr. 4) D) ect
				Code	V	(A)		Date Exerc	isable	Expiration Date	on Ti	Amount or Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
WEISS MICHAEL S 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	X					

Signatures

/s/ James F. Oliviero, Attorney-in-Fact	06/11/2021	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The 16,502 shares of restricted Common Stock will vest on June 10, 2024, subject to Mr. Weiss's continued service on the board on such date.
- (2) Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board.
- (3) The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.